Back to top

Analyst Blog

Bayer (BAYRY - Analyst Report) recently announced that it will not go ahead with its proposed acquisition of nutritional supplement company Schiff Nutrition International, Inc. .  Bayer had announced in October 2012 that it has inked a deal to buy Schiff Nutrition for $1.2 billion or $34.00 per share in cash. The agreement permitted Schiff Nutrition to review and accept an unsolicited offer within 30 days of inking the deal with Bayer.

Schiff Nutrition subsequently accepted the higher offer of the UK based consumer goods company Reckitt Benckiser Group plc . The consumer goods company inked a deal, earlier in the month, to buy Schiff Nutrition for $1.4 billion or $42.00 per share.

Management at Bayer stated that it still believes that had its proposed acquisition of Schiff Nutrition gone through it would have been a significant addition to the German company’s Consumer Care business. However, Bayer decided not to compromise on its offer and refused to enter into a bidding war with the UK based company as it was likely to result in an offer price above Bayer’s acceptable range.

Following the termination of the deal, Bayer received $22 million from Schiff Nutrition. Even though Bayer’s deal with Schiff Nutrition fell through, the former announced that it will not alter its policy of growth by acquisition.

We note that Bayer has been quite active on the acquisition front lately. In August 2012, the CropScience unit of Bayer acquired AgraQuest, Inc, formerly a global supplier of innovative biological pest management solutions. The acquisition has boosted Bayer’s fruits and vegetables business while building a strong technology platform based on "green" products.

Moreover, the decision of the HealthCare unit of Bayer to acquire Teva Pharmaceutical Industries Ltd. ‘s (TEVA - Analyst Report) animal health unit in the US is an encouraging move. The inclusion of Teva’s US animal health unit will not only add reproductive hormones to Bayer’s product portfolio, but also provide multiple anti-infective solutions for treating infections in livestock to Bayer‘s food animal unit. Following the completion of the deal in 2013, Bayer’s companion animal unit will boast of dermatological, pet wellness and nutraceutical offerings.

Our Recommendation

We have an Outperform recommendation on Bayer. The stock carries a Zacks #2 Rank (Buy rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%